冷循环微波消融联合肝动脉灌注化疗栓塞治疗原发性肝癌患者疗效及安全性研究

Clinical efficacy and safety of cool-tip m icrowave ablation com bining transcatheter arterial chem oem bolization in treatm ent of patients with prim ary liver cancer

目的探讨冷循环微波消融联合肝动脉灌注化疗栓塞(TACE)治疗原发性肝癌患者的疗效和安全性。方法将72例原发性肝癌患者随机分成观察组和对照组,每组36例。给予观察组冷循环微波消融联合TACE治疗,对照组行单纯TACE治疗,比较总有效率、生存率、血清甲胎蛋白(AFP)变化和不良反应。结果在治疗后6个月,观察组总有效率(88.9%)显著高于对照组(69.4%,x^2=4.12,P=0.04);观察组2a生存率(66.7%)显著高于对照组(41.7%,x^2=4.5,P=0.03);观察组血清AFP下降率(83.3%)显著高于对照组(61.1%,P<0.05);所有患者均未出现严重的不良反应。结论冷循环微波消融联合TACE治疗原发性肝癌患者安全有效。

Objective To study the clinical efficacy and safety of cool-tip microwave ablation combining transcatheter arterial chemoembolizatio （TACE） in treatment of patients with primary liver cancer （PLC）. Methods There were 72 patients with PLC in our series,and they were randomly divided into control group and observation group with 36 cases in each. The patients in the two groups were treated with cool-tip microwave ablation and TACE or TACE alone. The effective rate,two-year survival rate and serum alpha fetoprotein （AFP） reduction rate were evaluated. Results After 6 months of treatment,the total effective rate was 88.9% in the combination group,much higher than that （69.4%,x2=4.12,P=0.04） in TACE group;two-year survival rate was 66.7% in the combination group,much high than that （41.7%,x2=4.5,P=0.03） in the TACE group;serum AFP reduction rate was 83.3% in the combination group,significantly high than that （61.1%,P〈0.05） in TACE group;No serious adverse reaction was observed in the two groups. Conclusion Cool-tip microwave ablation combined with TACE in the treatment of patients with PLC is safe and effective.